The 36-month beta value for ANRO is also noteworthy at 1.59. There are mixed opinions on the stock, with 6 analysts rating it as a “buy”, 1 rating it as “overweight”, 1 rating it as “hold”, and 0 rating it as “sell”.
The public float for ANRO is 21.49M, and at present, short sellers hold a 13.00% of that float. The average trading volume of ANRO on July 04, 2025 was 305.73K shares.
ANRO stock’s latest price update
The stock of Alto Neuroscience Inc (NYSE: ANRO) has increased by 2.17% when compared to last closing price of $2.3. Despite this, the company has experienced a 2.17% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-30 that MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)—- $ANRO #PrecisionPsychiatry–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK government’s National Institute for Health and.
ANRO’s Market Performance
Alto Neuroscience Inc (ANRO) has experienced a 2.17% rise in stock performance for the past week, with a -10.65% drop in the past month, and a 14.63% rise in the past quarter. The volatility ratio for the week is 7.05%, and the volatility levels for the past 30 days are at 8.10% for ANRO. The simple moving average for the last 20 days is -1.45% for ANRO stock, with a simple moving average of -48.29% for the last 200 days.
Analysts’ Opinion of ANRO
Many brokerage firms have already submitted their reports for ANRO stocks, with Wedbush repeating the rating for ANRO by listing it as a “Neutral”. The predicted price for ANRO in the upcoming period, according to Wedbush is $4 based on the research report published on October 23, 2024 of the previous year 2024.
ANRO Trading at -4.17% from the 50-Day Moving Average
After a stumble in the market that brought ANRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.61% of loss for the given period.
Volatility was left at 8.10%, however, over the last 30 days, the volatility rate increased by 7.05%, as shares sank -4.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.98% upper at present.
During the last 5 trading sessions, ANRO rose by +2.17%, which changed the moving average for the period of 200-days by -82.75% in comparison to the 20-day moving average, which settled at $2.38. In addition, Alto Neuroscience Inc saw -79.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANRO starting from Savitz Adam, who purchase 12,069 shares at the price of $12.60 back on Jul 09 ’24. After this action, Savitz Adam now owns 36,920 shares of Alto Neuroscience Inc, valued at $152,085 using the latest closing price.
Savitz Adam, the CHIEF MEDICAL OFFICER of Alto Neuroscience Inc, purchase 2,931 shares at $13.22 during a trade that took place back on Jul 10 ’24, which means that Savitz Adam is holding 39,851 shares at $38,748 based on the most recent closing price.
Stock Fundamentals for ANRO
The total capital return value is set at -0.42%. Equity return is now at value -38.04%, with -33.09% for asset returns.
Based on Alto Neuroscience Inc (ANRO), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -12.01. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -162.18.
Currently, EBITDA for the company is -68.61 million with net debt to EBITDA at 2.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.53.
Conclusion
In summary, Alto Neuroscience Inc (ANRO) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
